Sun Young Rha
Overview
Explore the profile of Sun Young Rha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
407
Citations
8969
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moehler M, Oh D, Kato K, Arkenau T, Tabernero J, Lee K, et al.
Adv Ther
. 2025 Mar;
PMID: 40075025
Introduction: Tislelizumab plus investigator-chosen chemotherapy (ICC) demonstrated a statistically significant improvement in overall survival (OS) versus placebo plus ICC in RATIONALE-305 in patients with locally advanced unresectable or metastatic human...
2.
Giannatempo P, Machiels J, Sassa N, Arranz J, Fujii Y, Su W, et al.
Clin Genitourin Cancer
. 2025 Mar;
23(2):102273.
PMID: 40037029
Introduction: A post hoc analysis of efficacy and safety outcomes with pembrolizumab monotherapy was conducted in patients with advanced or metastatic urothelial carcinoma (UC) with pure transitional cell carcinoma (TCC)...
3.
Satoh T, Barthelemy P, Nogova L, Honda K, Hirano H, Lee K, et al.
Eur J Cancer
. 2025 Feb;
218:115262.
PMID: 39919334
Background And Aims: Aberrant fibroblast growth factor receptor (FGFR)-driven signaling, predominantly arising from FGFR2 amplification, plays a key role in gastric cancer pathogenesis. This open-label, phase 2 study evaluated the...
4.
Schram A, Goto K, Kim D, Macarulla T, Hollebecque A, OReilly E, et al.
N Engl J Med
. 2025 Feb;
392(6):566-576.
PMID: 39908431
Background: Neuregulin 1 () fusions are recurrent oncogenic drivers found in multiple solid tumors. NRG1 binds to human epidermal growth factor receptor 3 (HER3), leading to heterodimerization with HER2 and...
5.
Rha S, Zhang Y, Elme A, Pazo Cid R, Alacacioglu A, Ziogas D, et al.
JCO Precis Oncol
. 2025 Jan;
9:e2400710.
PMID: 39854659
Purpose: Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression is an emerging biomarker in gastric cancer and gastroesophageal junction cancer (GC). We assessed FGFR2b protein overexpression prevalence in...
6.
Kim T, Uyama I, Rha S, Bencivenga M, An J, Wyrwicz L, et al.
J Gastric Cancer
. 2025 Jan;
25(1):133-152.
PMID: 39822172
Conversion therapy is a treatment strategy that shifts from palliative systemic therapy to curative surgical treatment for primary and/or metastatic stage IV gastric cancer (GC). To address its clinical statements,...
7.
Ma H, Srivastava S, Ho S, Xu C, Lian B, Ong X, et al.
Cancer Discov
. 2025 Jan;
PMID: 39774838
Gastric cancer (GC) is a major cause of global cancer mortality with high levels of heterogeneity. To explore geospatial interactions in tumor ecosystems, we integrated 2,138 spatial transcriptomic regions-of-interest (ROIs)...
8.
Kim E, Kwon W, Kim T, Hwang J, Kim S, Rha S
Cancer Res Treat
. 2024 Dec;
PMID: 39668392
Purpose: To identify the anti-cancer effect and investigate the underlying mechanism of MPS1/TTK (Monopolar spindle 1; also known as threonine tyrosine kinase) inhibitor in gastric cancer (GC) cell lines. Materials...
9.
Kim H, Jung E, Kwon J, Kim Y, Koh S, Lee M, et al.
Cancer Res Treat
. 2024 Dec;
PMID: 39638249
Purpose: Identifying the palliative care needs of patients with advanced cancer is important for maintaining quality of life and timely transition to palliative care. We aimed to validate the Korean...
10.
Lee C, Choo J, Ahn Y, Kim J, Rha S, Rim C
Cancer Res Treat
. 2024 Dec;
57(1):11-18.
PMID: 39638248
During the celebration of the 50th anniversary of the founding of the Korean Cancer Association, articles published in Cancer Research and Treatment from 2004 to 2023 were assessed based on...